poisar

Stocks · News reference

Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes

Aug 28, 2026, 11:03 AMBenzinga Newsdesk

Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LLY
Source
benzinga
Observed
Aug 28, 2026, 11:03 AM
Checked
Aug 28, 2026, 11:03 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 28, 2026, 3:31 PMBrendan Coffey

    Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

    The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

    Read original at the-motley-fool
    BBHPJPAMGNLLYGILD
  2. Aug 28, 2026, 1:00 PMSns Insider

    Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS Insider

    The global breast cancer therapeutics market is projected to grow from USD 39.46 billion in 2025 to USD 95.14 billion by 2035, with a CAGR of 9.20%. Growth is driven by increased adoption of targeted therapies, CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates. North America leads with 38.61% market share, while Asia Pacific shows the fastest growth. Targeted therapy dominates with 64.85% share, while immunotherapy is the fastest-growing segment at 14.25% CAGR.

    Read original at globenewswire-inc
    RHHBYPFENVSAZNLLY
  3. Aug 28, 2026, 11:07 AMEric Volkman

    Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

    Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

    Read original at the-motley-fool
    RVMDRVMDWLLYJNJABBV